Skip to Content
Merck
  • Developing structure-activity relationships for the prediction of hepatotoxicity.

Developing structure-activity relationships for the prediction of hepatotoxicity.

Chemical research in toxicology (2010-06-18)
Nigel Greene, Lilia Fisk, Russell T Naven, Reine R Note, Mukesh L Patel, Dennis J Pelletier
ABSTRACT

Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems. This process can be supported by the use of existing toxicity data and mechanistic understanding of the biological processes for related compounds. In the published literature, this information is often spread across diverse sources and can be varied and unstructured in quality and content. The current work has explored whether it is feasible to collect and use such data for the development of new SARs for the hepatotoxicity endpoint and expand upon the limited information currently available in this area. Reviews of hepatotoxicity data were used to build a structure-searchable database, which was analyzed to identify chemical classes associated with an adverse effect on the liver. Searches of the published literature were then undertaken to identify additional supporting evidence, and the resulting information was incorporated into the database. This collated information was evaluated and used to determine the scope of the SARs for each class identified. Data for over 1266 chemicals were collected, and SARs for 38 classes were developed. The SARs have been implemented as structural alerts using Derek for Windows (DfW), a knowledge-based expert system, to allow clearly supported and transparent predictions. An evaluation exercise performed using a customized DfW version 10 knowledge base demonstrated an overall concordance of 56% and specificity and sensitivity values of 73% and 46%, respectively. The approach taken demonstrates that SARs for complex endpoints can be derived from the published data for use in the in silico toxicity assessment of new compounds.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
13-cis-Retinoic acid, ≥98% (HPLC)
Sigma-Aldrich
Amoxicillin, 95.0-102.0% anhydrous basis
Sigma-Aldrich
Folic acid, meets USP testing specifications
Sigma-Aldrich
Folic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥97%
Sigma-Aldrich
Folic acid, ≥97%
Sigma-Aldrich
Acetylcholine chloride, suitable for cell culture
Sigma-Aldrich
Menadione, meets USP testing specifications
Sigma-Aldrich
Ergocalciferol, 40,000,000 USP units/g
Sigma-Aldrich
L-Arginine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Caffeine, powder, ReagentPlus®
Sigma-Aldrich
Acetylcholine chloride, ≥99% (TLC)
Sigma-Aldrich
Rotenone, ≥95%
Sigma-Aldrich
Isoprenaline hydrochloride
Sigma-Aldrich
Nalidixic acid, ≥98%
Sigma-Aldrich
L-Arginine, reagent grade, ≥98%
Sigma-Aldrich
Caffeine, BioXtra
Sigma-Aldrich
Hydrochlorothiazide, crystalline
Sigma-Aldrich
Betamethasone, ≥98%
Sigma-Aldrich
Estradiol, meets USP testing specifications
Sigma-Aldrich
Caffeine, Sigma Reference Standard, vial of 250 mg
Sigma-Aldrich
Valproic acid sodium salt, 98%
Sigma-Aldrich
Caffeine, meets USP testing specifications, anhydrous
Sigma-Aldrich
Furosemide
Sigma-Aldrich
N-Acetyl-L-cysteine, BioReagent, suitable for cell culture
Sigma-Aldrich
Acetaminophen, BioXtra, ≥99.0%
Sigma-Aldrich
Gabapentin, solid
Sigma-Aldrich
Hydroxyurea, 98%, powder
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Adenosine, ≥99%
Sigma-Aldrich
Maleic acid, ReagentPlus®, ≥99% (HPLC)